Drug
Belumosudil
Belumosudil: highest development phase Post-Market, developed by Sanofi. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Belumosudil NCT07135973 | Post-Market | Chronic Graft Versus Host Disease |
| Belumosudil NCT07771439 | Phase 3 | Chronic Graft Versus Host Disease |
| Belumosudil NCT07726914 | Phase 1 | Chronic Graft Versus Host Disease |
Latest
Follow Belumosudil on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.